

Status: Currently Official on 16-Feb-2025

Official Date: Official as of 01-Aug-2017

Document Type: USP Monographs

DocId: GUID-70592DA8-D767-4817-B58E-6E762B3CF9FF_1_en-US

DOI: https://doi.org/10.31003/USPNF_M56220_01_01

DOI Ref: z3g89

© 2025 USPC
Do not distribute

Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate Ophthalmic Ointment

DEFINITION

Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc, and Hydrocortisone Acetate. It contains the equivalent of NLT 90.0% and NMT 140.0% of the labeled amounts of neomycin, polymyxin B, and bacitracin, and NLT 90.0% and NMT 110.0% of the labeled amount of hydrocortisone acetate ($C_{23}H_{32}O_6$).

IDENTIFICATION

- A. **THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201BNP):** Meets the requirements
- B. The retention time of the hydrocortisone acetate peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for *Hydrocortisone Acetate*.

ASSAY

• NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment in a separator with 50 mL of [ether](#). Extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

Acceptance criteria: 90.0%–140.0%

• POLYMYXIN B

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.6* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (10 polymyxin B Units/mL). Add to each *Test Dilution* of the standard a quantity of [USP Neomycin Sulfate RS](#), dissolved in *Buffer B.6*, to obtain the same concentration of neomycin as in the *Test Dilution* of the sample.

Acceptance criteria: 90.0%–140.0%

• BACITRACIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

Sample solution: Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of [0.01 N hydrochloric acid](#). Combine the acid extracts, and dilute with [0.01 N hydrochloric acid](#) to a suitable volume.

Analysis: Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.1* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (1.0 bacitracin Unit/mL). If the *Sample solution* has a concentration of less than 100 bacitracin Units/mL, add hydrochloric acid to each *Test Dilution* of the standard to obtain the same concentration of hydrochloric acid as in the *Test Dilution* of the sample.

Acceptance criteria: 90.0%–140.0%

• HYDROCORTISONE ACETATE

Mobile phase: [Butyl chloride](#), water-saturated [butyl chloride](#), [tetrahydrofuran](#), [methanol](#), and [glacial acetic acid](#) (475:475:70:35:30)

Standard solution: 0.10 mg/mL of [USP Hydrocortisone Acetate RS](#) in water-saturated [chloroform](#)

Sample solution: Nominally 0.10 mg/mL of hydrocortisone acetate from Ophthalmic Ointment prepared as follows. Transfer a portion of Ophthalmic Ointment containing nominally 2.5 mg of hydrocortisone acetate to a closable container. Add 25.0 mL of water-saturated [chloroform](#) and about 10 glass beads. Securely close the container, and shake vigorously for approximately 15 min. Centrifuge, and use the clear, lower chloroform layer.

Chromatographic system(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 254 nm**Column:** 3.9-mm × 30-cm; 10-μm packing [L3](#)**System suitability****Sample:** Standard solution**Suitability requirements****Relative standard deviation:** NMT 2.0%**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of hydrocortisone acetate ($C_{23}H_{32}O_6$) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the Sample solution r_S = peak response from the Standard solution C_S = concentration of [USP Hydrocortisone Acetate RS](#) in the Standard solution (mg/mL) C_U = nominal concentration of hydrocortisone acetate in the Sample solution (mg/mL)**Acceptance criteria:** 90.0%–110.0%**SPECIFIC TESTS**

- [STERILITY TESTS \(71\)](#): Meets the requirements
- **OTHER REQUIREMENTS:** It meets the requirements for Particulate and Foreign Matter and Container Contents in [Ophthalmic Products—Quality Tests \(771\), Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes. Store at controlled room temperature.

- [USP REFERENCE STANDARDS \(11\)](#):

[USP Bacitracin Zinc RS](#)[USP Hydrocortisone Acetate RS](#)[USP Neomycin Sulfate RS](#)[USP Polymyxin B Sulfate RS](#)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC, AND HYDROCORTISONE ACETATE OPHTHALMIC OINTMENT	Julie Zhang Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 39(5)

Current DocID: [GUID-70592DA8-D767-4817-B58E-6E762B3CF9FF_1_en-US](#)**DOI:** https://doi.org/10.31003/USPNF_M56220_01_01**DOI ref:** [z3g89](#)